2021-03 · Series B (database record) · Not disclosed ↗
LinkedIn company page
Independent company page not verified
The database lists Zhangjiang Torch Venture Capital. The company website confirms investors but does not specify the round.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The official pipeline explicitly lists HJ-002 and HJ-004 as EGFR PROTACs for NSCLC and advanced cancers, respectively.
Program / service
Target / indication
Representative stage
Evidence & scope
HJ-002
EGFR · See individual trial / indication; not individually confirmed in this review
Stage not disclosed
Human results not confirmed in this review
HJ-004
EGFR · See individual trial / indication; not individually confirmed in this review
Stage not disclosed
Human results not confirmed in this review
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
C4 Therapeutics reported completed enrollment of the first safety cohort in its Phase 1b cemsidomide–elranatamab combination trial. It expects Phase 2 MOMENTUM enrollment to finish in the first quarter of 2027, with initial response-rate data in the second half. At September 30, cash, cash equivalents and marketable securities totaled $274.7 million, with projected runway through 2028.
Pipeline stages are presented graphically and could not be reliably parsed from text in this review. Administration routes and human results were not confirmed.
Product pipeline ↗Jing Medicine Technology · Undated · 2026-10-31accessed
